

VIDEO INTERVIEW

Stable chronic angina: revascularization versus medical therapy

OVERVIEW

One of the major complications that can develop in patients with hypertension is coronary artery disease. The presence of stable coronary artery disease classifies a patient with hypertension as one at very high cardiovascular risk, irrespective of their blood pressure values (even if these are lower than 140 / 90 mmHg). Consequently, this pathological condition requires careful patient evaluation and appropriate treatment. Guidelines can help the clinician care for these patients, but it is important that signs and symptoms are carefully monitored and followed in individual patients to achieve the best outcome. An important issue is whether a patient with stable chronic angina should be revascularized or treated pharmacologically. In addition, for those for whom the choice is pharmacological treatment, what are the best options? This video interview will discuss the risks for patients with hypertension and stable coronary artery disease and the best therapeutic options to limit the negative cardiovascular consequences of the disease.

LEARNING OBJECTIVES

At the end of this activity, participants will be able to:

- Describe the pathogenetic mechanisms leading from hypertension to stable coronary artery disease
- Illustrate the cardiovascular risk linked to the presence of stable coronary artery disease
- Examine the evidence supporting revascularization of patients with stable coronary artery disease and discuss when the procedure is not appropriate
- Discuss the best therapeutic approach to improve outcomes in patients with hypertension and stable coronary artery disease

TARGET AUDIENCE

This activity is designed for Cardiologists, General Practitioners, Internists and those treating patients with cardiovascular disorders.



FACULTY

Felix Mahfoud

Associate Professor
Department of Internal Medicine III
Cardiology, Angiology, Intensive Care Medicine
Saarland University Hospital
Homburg, Germany

LANGUAGE

This activity will be in English, with Arabic and Mandarin Chinese subtitles.

For information about the program, please contact:

Scientific Seminars International Foundation

T +39 380 1504116 - F +39 06 4827169

info@scientificseminars.com

To access the resource online, click here and login:

<https://www.learning.scientificseminars.com/the-2021-digital-learning-journey-on-hypertension/video-interview/>

This independent educational program is made possible thanks to an educational grant received from Merck Healthcare KGaA, Darmstadt, Germany.

